| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Fibrinogen-Binding Peptide TFA targets fibrinogen directly, rather than the platelet GPIIb/IIIa receptor. By binding to fibrinogen, it inhibits both the adhesion of platelets to fibrinogen and platelet aggregation. It also inhibits platelet adhesion to vitronectin.
|
|---|---|
| ln Vitro |
In vitro, Fibrinogen-Binding Peptide TFA binds fibrinogen and inhibits platelet adhesion to fibrinogen and platelet aggregation. It also inhibits platelet adhesion to vitronectin. The TFA salt form provides enhanced aqueous solubility (200 mg/mL), eliminating the need for DMSO in platelet assays.
|
| ln Vivo |
Specific in vivo activity data for Fibrinogen-Binding Peptide TFA are not detailed in available sources. As an inhibitor of platelet adhesion and aggregation, it may have potential for in vivo studies in thrombosis and hemostasis models.
|
| Enzyme Assay |
Non-cellular binding assays for Fibrinogen-Binding Peptide TFA involve measuring its binding affinity to fibrinogen. These assays can be performed using surface plasmon resonance (SPR) or ELISA-based binding assays with purified fibrinogen protein and labeled peptide.
|
| Cell Assay |
In vitro cellular assays for Fibrinogen-Binding Peptide TFA are performed using platelet preparations. Platelets are treated with the peptide, and its ability to inhibit platelet adhesion to fibrinogen and platelet aggregation is measured. The TFA salt form enables solvent-free platelet assay workflows.
|
| Animal Protocol |
In vivo animal experiments for Fibrinogen-Binding Peptide TFA would typically be conducted in animal models of thrombosis. The compound would be administered via appropriate routes, and endpoints would include assessment of thrombus formation, platelet aggregation, and bleeding time.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties for Fibrinogen-Binding Peptide TFA are not detailed in available sources. The compound has a molecular weight of 679.6 g/mol and a molecular formula of C27H40F3N7O10. The TFA salt form is utilized to enhance solubility and stability for research applications.
|
| Toxicity/Toxicokinetics |
Toxicological data for Fibrinogen-Binding Peptide TFA are not provided in available sources. As a research peptide, its safety profile has not been extensively characterized. It is intended for research use only and not for human consumption.
|
| References | |
| Additional Infomation |
Fibrinogen-Binding Peptide TFA is a synthetic pentapeptide (H-Glu-His-Ile-Pro-Ala-OH) that binds fibrinogen and inhibits platelet adhesion and aggregation. It is a unique fibrinogen-targeting peptide for antithrombotic research. No clinical trial or regulatory approval information is available.
|
| Molecular Formula |
C27H40F3N7O10
|
|---|---|
| Molecular Weight |
679.64
|
| Related CAS # |
Fibrinogen-Binding Peptide;137235-80-4
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~250 mg/mL (~367.84 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4714 mL | 7.3568 mL | 14.7137 mL | |
| 5 mM | 0.2943 mL | 1.4714 mL | 2.9427 mL | |
| 10 mM | 0.1471 mL | 0.7357 mL | 1.4714 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA